Genetic Signatures Announces $30 Million Capital Raising
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The funds raised will support the commercialization of the Enteric Parasite product in the US and enhance the company's balance sheet. Eligible directors intend to participate in the entitlement offer, which will issue new shares that rank equally with existing shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Genetic Signatures Ltd. on 6ix
In the deck
Story so far
Earlier from Genetic Signatures
- Genetic Signatures Appoints Allison Rossiter As CEO
- FDA Clearance For Gastrointestinal Parasite Detection Kit
- Trading Halt
- Decision to Cease Development of US Respiratory Product
- Leadership Transition at Genetic Signatures
Later from Genetic Signatures
- FDA Clearance and Capital Raising Presentation
- Completion of Institutional Entitlement Offer and Placement
- Despatch Of Retail Entitlement Offer Booklet
- Appendix 4E and Annual Report
- 2024 AGM Chairman's Address and CEO Presentation
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures